Therapeutic Area: Oncology Product Name: Apealea
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Elevar Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 05, 2020
Tiba will be responsible for managing named-patient requests through which physicians can legally and ethically prescribe Apealea for patients prior to commercial availability, commercialize and distribute the product throughout the Middle East and North African region.